TransMedics Group, Inc. (TMDX)
Latest news, insights and market data
Market Data
AI Insights
TMDX is gaining attention for its OCS technology and global expansion, which bolster growth prospects. However, concerns about margin pressures and rising investments could impact performance. The upcoming Q3 earnings will be crucial to assess how these factors play out.
Latest News
| Title | Published |
|---|---|
Reasons to Retain TransMedics Stock in Your Portfolio for Now Reasons to Retain TransMedics Stock in Your Portfolio for Now | about 14 hours ago |
Reasons to Retain TransMedics Stock in Your Portfolio for Now TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns. | about 14 hours ago |
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings | about 18 hours ago |
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026. | about 18 hours ago |
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | 5 days ago |
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted stock units (RSUs) to nine employees. These awards were granted as a material inducement for each employee's entry into | 5 days ago |
TransMedics to Present at Upcoming Investor Conferences TransMedics to Present at Upcoming Investor Conferences | 6 days ago |
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted stock units (RSUs) to nine employees. These awards were granted as a material inducement for each employee's entry into
TransMedics to Present at Upcoming Investor Conferences
TransMedics to Present at Upcoming Investor Conferences